Sky RX
US$ 22.90
pharma news today obesity drugs glp-1 september 2025 Swiss Re says could reduce US mortality by up to 6.4% The GLP-1 Revolution Continues
Description
Accessed March 9, 2026.
now on LinkedIn
Beyond 6 Months: Long-Term Considerations GLP-1 medications for weight management are intended as long-term treatments, not short-term solutions
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Tirzepatide (mean difference 2.10% (95% confidence interval 2.47% to 1.74%), SUCRA 94.2%
these effects are primarily or partially dependent on activation of the PI3K/AKT pathway
